Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005624 · ClinicalTrials.gov registry record · Phase 2
CI-994 in Treating Patients With Advanced Myeloma
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00005624 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 6 participants.
The verdict
NCT00005624, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CI-994 in treating patients who have advanced myeloma.
Interventions
- DRUG CI-994
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 1997-08 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005624
The ClinicalTrials.gov registry entry for NCT00005624 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CI-994 is the first listed.
NCT00005624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005624 about?
NCT00005624 is a clinical study titled "CI-994 in Treating Patients With Advanced Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CI-994 in treating patients who have advanced myeloma.
What is the current status of trial NCT00005624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 1997-08. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00005624?
The interventions under investigation include: CI-994 (DRUG).
Who is sponsoring clinical trial NCT00005624?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.